Tirzepatide vs Semaglutide: What a Head-to-Head Trial Shows

Tirzepatide and semaglutide are related medications, but they are not the same drug. For chronic weight management, the relevant FDA-approved brands are Zepbound (tirzepatide) and Wegovy (semaglutide). Mounjaro and Ozempic contain the same respective active ingredients but have different labeled indications.

The best choice cannot be made from an average weight-loss number alone. Indication, medical history, contraindications, side effects, other medications, coverage, availability, and personal preference all matter.

What is different about the two drugs?

Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. Both FDA-approved weight-management products are used with reduced-calorie nutrition and increased physical activity under their labels.

The current labels contain the complete indications, administration instructions, contraindications, warnings, adverse reactions, and medication guides. Review the FDA prescribing information for Wegovy and Zepbound rather than relying on a social-media dose chart.

What did the direct comparison find?

The 2025 SURMOUNT-5 trial randomized 751 adults with obesity but without type 2 diabetes to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks. The average percentage change in body weight was 20.2% with tirzepatide and 13.7% with semaglutide. Gastrointestinal events were the most common adverse events in both groups and were mostly mild to moderate in severity during dose escalation.

Those are study-group averages, not promises for an individual. The trial was open-label, used specific doses and eligibility criteria, excluded adults with type 2 diabetes, and was funded by Eli Lilly, the manufacturer of tirzepatide. The result supports a difference in average weight reduction in that study population; it does not make tirzepatide the right choice for every person. Read the peer-reviewed trial abstract and the registered study record.

The safety discussion overlaps, but it is product-specific

Both labels describe common gastrointestinal adverse reactions and important warnings and precautions. These include risks involving pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, and hypoglycemia in certain medication combinations.

Both labels also carry a boxed warning about thyroid C-cell tumors found in rodents. It is unknown whether the drugs cause these tumors in humans. The products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Each label contains additional product-specific information, including considerations involving pregnancy, procedures involving anesthesia or deep sedation, and interactions or effects relevant to other medicines.

This is not a complete list. A clinician should review the current label and the patient’s complete situation.

Why “which one is stronger?” is incomplete

Average efficacy is one factor. A useful decision also considers:

• Whether the patient meets the labeled indication
• Relevant contraindications, precautions, and medication interactions
• Prior response and tolerability
• Diabetes status and other health conditions
• Pregnancy plans
• Insurance formulary, prior authorization, and out-of-pocket cost
• Ability to obtain and continue the exact product
• The patient’s goals and preferences

A lower average in one trial does not mean a medication “failed,” and a higher average does not guarantee an individual response.

Brand and compounded versions must not be blurred

A compounded semaglutide or tirzepatide preparation is not FDA-approved and is not an FDA-approved generic version of Wegovy or Zepbound. FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.

The shortage-based enforcement-discretion periods for semaglutide and tirzepatide injections ended in 2025. FDA’s 2026 update explains restrictions on regularly compounding products that are essentially copies of commercially available drugs and the need for an identified patient-specific significant difference in relevant circumstances. See FDA’s GLP-1 compounding update and current safety concerns about unapproved GLP-1 drugs.

Do not transfer the trial percentages or FDA-approved label claims above to a compounded product. They are different products with different regulatory status.

Questions to resolve with a clinician

Instead of asking only which drug “wins,” ask:

1. What exact product and indication are we discussing?
2. What part of my history changes the benefit-risk balance?
3. What alternatives, including non-medication options, should I consider?
4. What would we monitor, and what would make us pause, change, or stop?
5. What is the total cost and likely coverage path?
6. If a compounded product is proposed, what documented patient-specific need supports it and which pharmacy will dispense it?

How Viva handles the decision

The anonymous guide on this website cannot choose a drug or establish eligibility. At a first visit, Liliana Damron, APRN, FNP-BC, reviews the information relevant to the decision and explains whether Viva’s telehealth scope is appropriate. A plan selection does not guarantee a prescription.

Viva is based in Austin and currently serves adults physically located in Texas, Colorado, Florida, or Iowa at the time of care. Read the weight-management page and published care and pricing before booking.

Educational content only. This comparison does not recommend a product, predict an outcome, or replace individualized medical advice or the current FDA-approved labeling.